8-K: Stereotaxis Reports Lower Than Expected Q2 2024 Results Amid Strategic Progress

Stereotaxis reported financial results for the second quarter of 2024 that fell below expectations, despite significant progress in strategic innovation and a confident outlook for the second half of the year.

Summary

• Stereotaxis announced its financial results for the second quarter of 2024, with revenue totaling $4.5 million, compared to $7.9 million in the same period last year.
• System revenue was $0.2 million, and recurring revenue was $4.3 million, compared to $3.3 million and $4.6 million, respectively, in the prior year.
• The company attributed the weaker system revenue to delays in hospital construction schedules.
• The gross margin for the quarter was 74%.
• Operating expenses were $9.3 million, including $2.5 million in non-cash stock compensation expense.
• Adjusted operating expenses, excluding stock compensation, were $6.8 million, compared to $6.9 million in the prior year.
• The operating loss and net loss for the quarter were $6.0 million and $5.8 million, respectively.
• Adjusted operating loss and adjusted net loss, excluding stock compensation, were $3.5 million and $3.3 million, respectively.
• Negative free cash flow for the quarter was $3.1 million.
• As of June 30, 2024, Stereotaxis had $15.2 million in cash and cash equivalents, including restricted cash, and no debt.
• The company expects greater than $14 million in revenue in the second half of the year and projects full-year revenue to be approximately equal to the previous year.
• Stereotaxis anticipates ending the year with approximately $13 million in cash and no debt, believing its balance sheet is sufficient to advance its product ecosystem, fund commercialization, and reach profitability without additional financing.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company reported lower-than-expected results and faces challenges, it also highlighted significant progress in innovation and expressed confidence in future performance. The acquisition of APT and the introduction of GenesisX are positive developments, but the financial results and delays weigh on the overall sentiment.

Positives

• The company made substantial progress with regulatory reviews of MAGiC in Europe and the US.
• Successful acquisition of Access Point Technologies (APT).
• Introduction of the next-generation robotic system, GenesisX.
• High confidence in significantly improved revenue and cash flow in the second half of the year.
• Multiple Genesis systems are in transit to customers.
• Active late-stage pipeline with additional orders expected near-term.
• Expects balance sheet to allow advancement of product ecosystem, fund commercialization, and reach profitability without additional financing.

Negatives

• Commercial results for the first half of the year were below expectations.
• Delayed recognition of revenue from the capital backlog.
• System revenue of $0.2 million was weaker than expected due to delays in hospital construction schedules.
• Operating loss and net loss for the second quarter of 2024 were ($6.0) million and ($5.8) million, respectively.
• Negative free cash flow for the second quarter was ($3.1) million.

Risks

• The company may face challenges in managing expenses at sustainable levels.
• Market acceptance of the company
• s products is uncertain.','Global economic conditions could impact customers' ability and willingness to purchase technology.','The company faces competition from other companies in the industry.','Changes in healthcare policy could affect the company's business.','Dependence on third-party vendors may pose risks.','Timing of regulatory approvals is uncertain.','The impact of pandemics or other disasters could disrupt operations.','Integration of the recent acquisition of APT may present challenges.','Some purchase orders and commitments are subject to contingencies outside the company's control and may be revised, modified, delayed, or canceled.'

Future Outlook

Stereotaxis expects greater than $14 million in revenue in the second half of this year, driven by stable recurring revenue and current Genesis system shipments. Full-year revenue is projected to be approximately equal to the previous year. The company anticipates ending the year with around $13 million in cash and no debt. These projections do not include potential revenue from APT, GenesisX, or MAGiC. Stereotaxis believes its current financial position will enable it to advance its product ecosystem, fund commercialization, and achieve profitability without needing additional financing.

Management Comments

• We made significant progress over the last quarter on strategic innovation efforts that are establishing a solid foundation upon which to build a substantial and successful company.
• Key milestones achieved include successfully obtaining CE mark in Europe and submitting a 510(k) application in the US for GenesisX, substantial progress with regulatory reviews of MAGiC in Europe and the US, and closing the acquisition of Access Point Technologies (APT).
• We have attempted to realize our strategic transformation while maintaining commercial momentum and preserving financial strength.
• Commercial results for the first half of the year were below expectations with delayed recognition of revenue from our capital backlog.
• Our visibility into the second half of this year provides high confidence in significantly improved revenue and cash flow.
• Multiple Genesis systems are in transit to customers with revenue to be recognized and cash received at delivery.
• We have an active late-stage pipeline with additional orders expected near-term.

Industry Context

This announcement reflects broader trends in the medical robotics industry, where companies are investing heavily in innovation and facing challenges related to regulatory approvals, hospital construction timelines, and market adoption. The focus on minimally invasive procedures and robotic precision aligns with the growing demand for advanced surgical technologies.

Comparison to Industry Standards

• Compared to Intuitive Surgical, a leader in the surgical robotics market with a much larger revenue base, Stereotaxis is a smaller player with a niche focus on endovascular intervention. Intuitive Surgical reported revenue of $1.5 billion in the most recent quarter, significantly higher than Stereotaxis.
• Medtronic, another major player in the medical device industry, has a diverse portfolio that includes robotic-assisted surgery platforms. Medtronic's revenue in the surgical segment alone surpasses Stereotaxis' total revenue.
• Stryker Corporation, known for its Mako robotic arm for orthopedic surgery, also demonstrates higher revenue figures compared to Stereotaxis.
• Mazor Robotics, acquired by Medtronic, was a competitor in the spinal surgery robotics space, showcasing the trend of consolidation in the industry.
• Stereotaxis
• focus on endovascular intervention sets it apart, but its financial performance lags behind these larger, more diversified companies in the medical technology sector.'

Stakeholder Impact

• Shareholders may be impacted by the lower-than-expected financial results and the associated fluctuations in stock price.
• Employees are likely focused on achieving the company
• s strategic goals and improving performance in the second half of the year.','Customers, particularly hospitals, may experience delays in receiving and implementing the company's systems due to construction schedules.','Suppliers and vendors may be affected by the company's management of expenses and procurement decisions.','Creditors are not directly impacted as the company currently has no debt.'

Next Steps

• Continue to advance the transformative product ecosystem to market.
• Focus on commercialization efforts.
• Monitor and manage expenses to achieve profitability.
• Secure additional orders from the active late-stage pipeline.
• Recognize revenue and receive cash from the delivery of Genesis systems currently in transit.

Key Dates

Keywords

Surgical Robotics, Endovascular Intervention, Medical Devices, GenesisX, MAGiC, Access Point Technologies, Minimally Invasive Therapy, Interventional Laboratory, Robotic Precision, Stereotaxis